Phospholipase A2 Receptor, Enzyme Linked Immunosorbent Assay, Serum
Use
Membranous nephropathy (MN) is a rare disease characterized by the deposition of immune complexes at the glomerular basement membrane. In approximately 70% of primary membranous nephropathy (pMN) cases, these complexes consist of autoantibodies against the M-type phospholipase A2 receptor (PLA2R) on podocytes. The levels of anti-PLA2R autoantibodies correlate with disease activity and progression. Detecting these autoantibodies aids in distinguishing primary MN from other nephrotic syndromes, especially when kidney biopsy is impractical. The presence of elevated anti-PLA2R can predict recurrence in patients awaiting kidney transplantation.
Special Instructions
Not provided.
Limitations
The absence of anti-PLA2R autoantibodies does not rule out primary membranous nephropathy. Single test results should not be solely used to diagnose membranous nephropathy. The test is not a standalone diagnostic tool and should be correlated with clinical information and other laboratory test results.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Phospholipase A2 Receptor
Protein
LOINC Codes
- 73737-9 - PLA2R IgG Ser IA-aCnc
- 73737-9 - PLA2R IgG Ser IA-aCnc
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into plastic vial within 2 hours of collection
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |